PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Complejo Hospitalario Universitario de Albacete](/img/noimage_org.png)
Complejo Hospitalario Universitario de Albacete
Albacete, EspañaPublicaciones en colaboración con investigadores/as de Complejo Hospitalario Universitario de Albacete (8)
2024
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
2022
-
Genomic mapping of copy number variations influencing immune response in breast cancer
Frontiers in Oncology, Vol. 12
2021
-
Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer
Cancers, Vol. 13, Núm. 16
-
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580
2020
-
Genomic mapping identifies mutations in ryr2 and ahnak as associated with favorable outcome in basal-like breast tumors expressing pd1/pd-l1
Cancers, Vol. 12, Núm. 8, pp. 1-15
2019
-
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
Frontiers in Immunology, Vol. 10
2016
-
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 805-812
2014
-
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279